A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Clinical trial NCT06548100 · COMPLETED
Trial details
- NCT number
- NCT06548100
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-16
- Primary completion
- 2026-07-09
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.